Found: 12
Select item for more details and to access through your institution.
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.
- Published in:
- Cells (2073-4409), 2019, v. 8, n. 12, p. 1522, doi. 10.3390/cells8121522
- By:
- Publication type:
- Article
Anti‐CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping.
- Published in:
- Transfusion, 2022, v. 62, n. 11, p. 2334, doi. 10.1111/trf.17137
- By:
- Publication type:
- Article
Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 20, p. 20332, doi. 10.1002/cam4.6619
- By:
- Publication type:
- Article
Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells.
- Published in:
- Frontiers in Immunology, 2020, v. 11, p. N.PAG, doi. 10.3389/fimmu.2020.01771
- By:
- Publication type:
- Article
Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123.
- Published in:
- Nature Biotechnology, 2023, v. 41, n. 9, p. 1296, doi. 10.1038/s41587-022-01626-2
- By:
- Publication type:
- Article
Construction and optimization of gene expression signatures for prediction of survival in two-arm clinical trials.
- Published in:
- BMC Bioinformatics, 2020, v. 21, n. 1, p. 1, doi. 10.1186/s12859-020-03655-7
- By:
- Publication type:
- Article
Pseudomonas exotoxin exhibits increased sensitivity to furin when sequences at the cleavage site are mutated to resemble the arginine-rich loop of diphtheria toxin.
- Published in:
- Molecular Microbiology, 1996, v. 22, n. 4, p. 769, doi. 10.1046/j.1365-2958.1996.d01-1721.x
- By:
- Publication type:
- Article
Erratum to: Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC).
- Published in:
- 2017
- By:
- Publication type:
- journal article
Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC).
- Published in:
- 2016
- By:
- Publication type:
- journal article
Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer.
- Published in:
- Cancer Science, 2019, v. 110, n. 11, p. 3565, doi. 10.1111/cas.14198
- By:
- Publication type:
- Article